PMID- 37279329 OWN - NLM STAT- MEDLINE DCOM- 20230906 LR - 20230912 IS - 1460-2377 (Electronic) IS - 0953-8178 (Linking) VI - 35 IP - 9 DP - 2023 Sep 5 TI - Foxp3 and Bcl6 deficiency synergistically induces spontaneous development of atopic dermatitis-like skin disease. PG - 423-435 LID - 10.1093/intimm/dxad018 [doi] AB - Atopic dermatitis (AD) is a common chronic skin disease caused by immune dysfunction, specifically the hyperactivation of Th2 immunity. AD is a complex disease with multiple factors contributing to its development; however, the interaction between these factors is not fully understood. In this study, we demonstrated that the conditional deletion of both the forkhead box p3 (Foxp3) and B-cell lymphoma 6 (Bcl6) genes induced the spontaneous development of AD-like skin inflammation with hyperactivation of type 2 immunity, skin barrier dysfunction, and pruritus, which were not induced by the single deletion of each gene. Furthermore, the development of AD-like skin inflammation was largely dependent on IL-4/13 signaling but not on immunoglobulin E (IgE). Interestingly, we found that the loss of Bcl6 alone increased the expression of thymic stromal lymphopoietin (TSLP) and interleukin (IL)-33 in the skin, suggesting that Bcl6 controls Th2 responses by suppressing TSLP and IL-33 expression in epithelial cells. Our results suggest that Foxp3 and Bcl6 cooperatively suppress the pathogenesis of AD. Furthermore, these results revealed an unexpected role of Bcl6 in suppressing Th2 responses in the skin. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of The Japanese Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Tai, Yuki AU - Tai Y AD - Laboratory of Pharmaceutical Immunology, Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan. FAU - Sakaida, Yuki AU - Sakaida Y AD - Laboratory of Pharmaceutical Immunology, Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan. FAU - Kawasaki, Riyo AU - Kawasaki R AD - Laboratory of Pharmaceutical Immunology, Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan. FAU - Kanemaru, Kaori AU - Kanemaru K AD - Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba 278-8510, Japan. FAU - Akimoto, Kazunori AU - Akimoto K AD - Laboratory of Molecular Medical Science, Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan. FAU - Brombacher, Frank AU - Brombacher F AD - Division of Immunology, Health Science Faculty, International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town Component & Institute of Infectious Diseases and Molecular Medicine (IDM), University of Cape Town, Cape Town 7701, South Africa. FAU - Ogawa, Shuhei AU - Ogawa S AD - Division of Integrated Research, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Chiba 278-0022, Japan. FAU - Nakamura, Yoshikazu AU - Nakamura Y AD - Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba 278-8510, Japan. FAU - Harada, Yohsuke AU - Harada Y AUID- ORCID: 0000-0002-8023-1030 AD - Laboratory of Pharmaceutical Immunology, Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Int Immunol JT - International immunology JID - 8916182 RN - 0 (Cytokines) RN - GT0IL38SP4 (Thymic Stromal Lymphopoietin) SB - IM MH - Humans MH - *Dermatitis, Atopic MH - Cytokines/metabolism MH - Skin MH - Pruritus MH - Thymic Stromal Lymphopoietin MH - Inflammation/metabolism OTO - NOTNLM OT - IL-13 OT - IL-33 OT - IL-4 OT - Th2 OT - Treg EDAT- 2023/06/06 19:13 MHDA- 2023/09/06 06:42 CRDT- 2023/06/06 14:32 PHST- 2023/04/12 00:00 [received] PHST- 2023/05/01 00:00 [accepted] PHST- 2023/09/06 06:42 [medline] PHST- 2023/06/06 19:13 [pubmed] PHST- 2023/06/06 14:32 [entrez] AID - 7189815 [pii] AID - 10.1093/intimm/dxad018 [doi] PST - ppublish SO - Int Immunol. 2023 Sep 5;35(9):423-435. doi: 10.1093/intimm/dxad018.